These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 38487533)

  • 1. Checkpoint CD24 function on tumor and immunotherapy.
    Huang S; Zhang X; Wei Y; Xiao Y
    Front Immunol; 2024; 15():1367959. PubMed ID: 38487533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
    Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
    Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.
    Li X; Tian W; Jiang Z; Song Y; Leng X; Yu J
    Cancer Immunol Immunother; 2024 Jan; 73(2):31. PubMed ID: 38279998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD24: A Novel Target for Cancer Immunotherapy.
    Panagiotou E; Syrigos NK; Charpidou A; Kotteas E; Vathiotis IA
    J Pers Med; 2022 Jul; 12(8):. PubMed ID: 36013184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
    Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleophosmin/B23 promotes endometrial cancer cell escape from macrophage phagocytosis by increasing CD24 expression.
    Lin CY; Tsai CL; Chao A; Lee LY; Chen WC; Tang YH; Chao AS; Lai CH
    J Mol Med (Berl); 2021 Aug; 99(8):1125-1137. PubMed ID: 33954835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners.
    Söhngen C; Thomas DJ; Skowron MA; Bremmer F; Eckstein M; Stefanski A; Driessen MD; Wakileh GA; Stühler K; Altevogt P; Theodorescu D; Klapdor R; Schambach A; Nettersheim D
    FEBS J; 2023 Oct; 290(20):4864-4876. PubMed ID: 37254618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer.
    Mishra AK; Ye T; Banday S; Thakare RP; Su CT; Pham NNH; Ali A; Kulshreshtha A; Chowdhury SR; Simone TM; Hu K; Zhu LJ; Eisenhaber B; Deibler SK; Simin K; Thompson PR; Kelliher MA; Eisenhaber F; Malonia SK; Green MR
    Cell Rep; 2024 Apr; 43(4):114041. PubMed ID: 38573857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unravelling CD24-Siglec-10 pathway: Cancer immunotherapy from basic science to clinical studies.
    Hazra R; Chattopadhyay S; Mallick A; Gayen S; Roy S
    Immunology; 2024 Nov; 173(3):442-469. PubMed ID: 39129256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10.
    Yin SS; Gao FH
    Front Immunol; 2020; 11():1324. PubMed ID: 32765491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel insights into the function of CD24: A driving force in cancer.
    Altevogt P; Sammar M; Hüser L; Kristiansen G
    Int J Cancer; 2021 Feb; 148(3):546-559. PubMed ID: 32790899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200.
    Moon SY; Han M; Ryu G; Shin SA; Lee JH; Lee CS
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis.
    Chen C; Zhang L; Ruan Z
    Mol Pharm; 2023 Feb; 20(2):971-986. PubMed ID: 36547230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation.
    Zhao M; Li J; Chen F; Han Y; Chen D; Hu H
    J Control Release; 2023 Mar; 355():211-227. PubMed ID: 36736908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CD24 in Cancer Immunotherapy.
    Chen W; Hu Z; Guo Z
    Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biological roles of CD24 in ovarian cancer: old story, but new tales.
    Gu Y; Zhou G; Tang X; Shen F; Ding J; Hua K
    Front Immunol; 2023; 14():1183285. PubMed ID: 37359556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy.
    Ni YH; Zhao X; Wang W
    Curr Gene Ther; 2020; 20(2):109-126. PubMed ID: 32576128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of CD24 as a new molecular marker in ovarian cancer.
    Tarhriz V; Bandehpour M; Dastmalchi S; Ouladsahebmadarek E; Zarredar H; Eyvazi S
    J Cell Physiol; 2019 Mar; 234(3):2134-2142. PubMed ID: 30317611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.